Literature DB >> 2531148

A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2'-[18F]fluoroethyl)spiperone and dynamic positron emission tomography.

S C Huang1, M M Bahn, J R Barrio, J M Hoffman, N Satyamurthy, R A Hawkins, J C Mazziotta, M E Phelps.   

Abstract

Dopamine D2-receptor density in striatum of monkey was measured with 3-(2'-[18F]fluoroethyl)spiperone (FESP) and dynamic positron emission tomography (PET), using a double-injection technique. A first bolus of high specific activity (SA) FESP (5 mCi; approximately equal to 1 Ci/mumol) was injected i.v.; 90 min later, a second bolus of lower SA FESP (5 mCi; approximately equal to 0.04 Ci/mumol) was injected. A dynamic PET study was performed to measure the kinetics of FESP in striatum over 180 min, and the metabolite-corrected concentration of FESP in plasma as a function of time was obtained from arterial blood samples. A nonlinear compartmental model that took into account the saturability of the receptor binding was used to describe the kinetics of FESP in striatum. Model parameters were estimated by regression with a constraint based on information about the equilibrium dissociation constant of the ligand-receptor binding. Dopamine D2-receptor density in striatum was estimated to be 25.9 +/- 12.7 pmol/g in seven Macaca nemestrina monkeys. The method does not require the use of cerebellum as a reference tissue region and an estimate of dopamine D2-receptor density can be obtained from a single study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531148     DOI: 10.1038/jcbfm.1989.119

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  11 in total

Review 1.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 2.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

3.  Rapid dual-injection single-scan 13N-ammonia PET for quantification of rest and stress myocardial blood flows.

Authors:  T C Rust; E V R DiBella; C J McGann; P E Christian; J M Hoffman; D J Kadrmas
Journal:  Phys Med Biol       Date:  2006-10-03       Impact factor: 3.609

4.  Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data.

Authors:  Marc D Normandin; Evan D Morris
Journal:  Neuroimage       Date:  2007-10-05       Impact factor: 6.556

Review 5.  Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man.

Authors:  B Sadzot; G Franck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

6.  Single-scan rest∕stress imaging (18)F-labeled flow tracers.

Authors:  Nathaniel Alpert; Yu-Hua Dean Fang; Georges El Fakhri
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

Review 7.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging.

Authors:  Kenneth M Tichauer; Yu Wang; Brian W Pogue; Jonathan T C Liu
Journal:  Phys Med Biol       Date:  2015-07-02       Impact factor: 3.609

Review 8.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

9.  Rinsing paired-agent model (RPAM) to quantify cell-surface receptor concentrations in topical staining applications of thick tissues.

Authors:  Xiaochun Xu; Yu Wang; Jialing Xiang; Jonathan T C Liu; Kenneth M Tichauer
Journal:  Phys Med Biol       Date:  2017-05-26       Impact factor: 3.609

Review 10.  Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Authors:  Alan J Fischman; Nathaniel M Alpert; Robert H Rubin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.